In vivo processed fragments of IGF binding protein-2 copurified with bioactive IGF-II

被引:7
作者
Ständker, L
Kübler, B
Obendorf, M
Braulke, T
Forssmann, WG
Mark, S
机构
[1] IPF PharmaCeut GmbH, D-30625 Hannover, Germany
[2] Univ Hamburg, Childrens Hosp, Hamburg, Germany
[3] Boehringer Mannheim GmbH, D-6800 Mannheim, Germany
关键词
hemofiltrate; insulin-like growth factor; IGF binding protein-2; cell viability; proteolysis; chromatography; RP-HPLC;
D O I
10.1016/S0006-291X(03)00658-2
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Proteolysis of insulin-like growth factor binding proteins (IGFBPs), the major carrier of insulin-like growth factors (IGFs) in the circulation, is an essential mechanism to regulate the bioavailability and half-live of IGFs. Screening for peptides in human hemofiltrate, stimulating the survival of PC-12 cells, resulted in the isolation of C-terminal IGFBP-2 fragments and intact IGF-II coeluting during the chromatographic purification procedure. The IGFBP-2 fragments exhibited molecular masses of 12.7 and 12.9 kDa and started with Gly 169 and Gly 167, respectively. The fragments were able to bind both IGFs. The stimulatory effect of the purified fraction on the survival of the PC-12 cells could be assigned exclusively to IGF-II, since it was abolished by the addition of neutralizing IGF-II antibodies. We suggest that in the circulation IGF-II is not only complexed with intact IGFBP but also with processed IGFBP-2 fragments not impairing the biological activity of IGF-II. (C) 2003 Elsevier Science (USA). All rights reserved.
引用
收藏
页码:708 / 713
页数:6
相关论文
共 25 条
[2]   VARIABLES CONTROLLING THE SECRETION OF INSULIN-LIKE GROWTH-FACTOR BINDING PROTEIN-2 IN NORMAL HUMAN-SUBJECTS [J].
CLEMMONS, DR ;
SNYDER, DK ;
BUSBY, WH .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1991, 73 (04) :727-733
[3]   Natural proteolytic processing of hemofiltrate CC chemokine 1 generates a potent CC chemokine receptor (CCR)1 and CCR5 agonist with anti-HIV properties [J].
Detheux, M ;
Ständker, L ;
Vakili, J ;
Münch, J ;
Forssmann, U ;
Adermann, K ;
Pöhlmann, S ;
Vassart, G ;
Kirchhoff, F ;
Parmentier, M ;
Forssmann, WG .
JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 192 (10) :1501-1508
[4]  
FORSSMANN WG, 1993, PEPTIDE CHEMISTRY 1992, P553
[5]   MEASUREMENT AND CHARACTERIZATION OF INSULIN-LIKE GROWTH-FACTOR BINDING PROTEIN-3 IN HUMAN BIOLOGICAL-FLUIDS - DISCREPANCIES BETWEEN RADIOIMMUNOASSAY AND LIGAND BLOTTING [J].
GARGOSKY, SE ;
PHAM, HM ;
WILSON, KF ;
LIU, F ;
GIUDICE, LC ;
ROSENFELD, RG .
ENDOCRINOLOGY, 1992, 131 (06) :3051-3060
[6]   Characterization of truncated insulin-like growth factor-binding protein-2 in human milk [J].
Ho, PJ ;
Baxter, RC .
ENDOCRINOLOGY, 1997, 138 (09) :3811-3818
[7]   Mutation of the RGD sequence does not affect plasma membrane association and growth inhibitory effects of elevated IGFBP-2 in vivo [J].
Hoeflich, A ;
Reisinger, R ;
Vargas, GA ;
Elmlinger, MW ;
Schuett, B ;
Jehle, PM ;
Renner-Müller, I ;
Lahm, H ;
Russo, VC ;
Wolf, E .
FEBS LETTERS, 2002, 523 (1-3) :63-67
[8]  
JAMES R, 1984, ANNU REV BIOCHEM, V53, P259
[9]   Isolation and characterization of circulating fragments of the insulin-like growth factor binding protein-3 [J].
Kübler, B ;
Draeger, C ;
John, H ;
Andag, U ;
Scharf, JG ;
Forssmann, WG ;
Braulke, T ;
Ständker, L .
FEBS LETTERS, 2002, 518 (1-3) :124-128
[10]   LEKTI, a novel 15-domain type of human serine proteinase inhibitor [J].
Mägert, HJ ;
Ständker, L ;
Kreutzmann, P ;
Zucht, HD ;
Reinecke, M ;
Sommerhoff, CP ;
Fritz, H ;
Forssmann, WG .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (31) :21499-21502